22.03.2023
An article entitled “C-reactive Protein Apheresis in Acute Myocardial Infarction” was published in the journal Current Pharmaceutical Design, April 2023 issue, and addresses the topic of C-reactive protein apheresis (CRP-A) therapy in patients with acute myocardial infarction.
28.11.2022
The FDA has granted PentraSorb CRP designation as a Breakthrough Device. A remarkable achievement.
31.10.2022
A further analyses of out CAMI-1 study hast been published as a feature paper in the Journal of Clinical Medicine.
09.09.2022
The IGG WB current newsletter of the Brandenburg Healthcare Initiative, issue 2/2022, reports on Pentracor GmbH and describes it as innovative.
22.06.2022
This editorial was published in the Journal of Clinical Medicine.
Berlin, 25.03.2022
The article appeared in the renowned magazine "Medical Clinic - Intensive Care Medicine and Emergency Medicine" in issue 117 on pages 191-199.
Berlin, 03.06.2022
The pharmacy magazine Mylife has published an interview with a heart attack patient and his doctor. Our managing director also has his say here. The original article can be found on pages 52 - 45 of issue 11/2022.
20.05.2022
The Pentracor is at the Heart Days of the German Society of Cardiology 2022 on September 29th. – 01.10.2022 represented in Bonn.
19.05.2022
Pentracast is the name of our new, informative podcast in which various employees, users and many others answer questions from our medical device consultant Henrike Weß.
This is the second part of the conversation between Henrike and Oliver
Hennigsdorf, 3. Mai 2022 – Das von der Pentracor GmbH (Wandelanleihe ISIN DE000A289XB9, WKN: A289XB) mit Sitz im brandenburgischen Hennigsdorf entwickelte und patentierte Blutwäscheverfahren CRP-Apherese macht es zum ersten Mal möglich, das pathologische Protein CRP in der klinischen Praxis schnell und effizient zu entfernen. Patienten profitieren enorm. Kliniken in Deutschland wenden die Therapie erfolgreich an.…
